The president at Cala Health discussed the clinical role, evidence base, and potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.
Kate Rosenbluth, PhD
Advertisement
President and co-founder at Cala Health.
Articles by Kate Rosenbluth, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
2
ELEVIDYS Shows Functional Benefits in Patients With DMD, Dompé Launches Phase 2 Trial of Intranasal Nerve Growth Factor in CP, NeurologyLive Roundtable: The Road Ahead for Precision Medicine in MS
3
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
4
TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome
5